Multicenter, double blind, prospective study assessing ability of molecular panel as a predictive determinant for panitunumab plus FOLFOX (oxaliplatin, 5-fluorouracil and leucovorin) therapy in treating patients with K-ras and n-ras wild type metastatic colorectal cancer.
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms SUPER-PEAK
- 07 Dec 2016 New trial record
- 11 Oct 2016 Trial design presented at 41st European Society for Medical Oncology Congress.